Diabetic Retinopathy

1. Topic Overview (Clinical Overview)

Summary

Diabetic Retinopathy (DR) is a microvascular complication of diabetes mellitus affecting the retina and representing the leading cause of preventable blindness in working-age adults in developed countries. [1,2] The condition results from chronic hyperglycaemia-induced damage to retinal capillaries, leading to progressive retinal ischaemia, vascular leakage, and pathological neovascularisation.

DR progresses through distinct stages: Non-Proliferative Diabetic Retinopathy (NPDR) – subdivided into Background (R1), Pre-Proliferative (R2) – and Proliferative Diabetic Retinopathy (PDR, R3), characterised by neovascularisation (fragile new vessel growth on the retina or optic disc). [3] These aberrant vessels carry high risk of vitreous haemorrhage and tractional retinal detachment, both sight-threatening complications.

Diabetic Macular Oedema (DMO or Maculopathy, M1) – characterised by retinal thickening or hard exudates affecting the macula – can occur at any stage of retinopathy and represents the primary cause of moderate vision loss in diabetic patients. [4] The pathophysiology centres on breakdown of the blood-retinal barrier mediated by Vascular Endothelial Growth Factor (VEGF) and other inflammatory cytokines.

Management strategies encompass systematic screening (annual digital retinal photography), rigorous systemic control (glycaemic, blood pressure, and lipid optimisation), intravitreal anti-VEGF therapy for macular oedema and selected cases of proliferative disease, pan-retinal photocoagulation (PRP) for proliferative retinopathy, and vitreoretinal surgery for advanced complications. Early detection through screening and timely intervention can prevent severe visual loss in the majority of cases. [5,6]

Key Facts

• Global Epidemiology: Approximately 35% of patients with diabetes mellitus have some degree of DR; 7% have sight-threatening disease (PDR or DMO). [7]
• Leading Cause of Blindness: DR is the most common cause of blindness in adults aged 20-74 years in developed nations. [2]
• Classification Systems: UK National Screening Committee (NSC) and ETDRS (Early Treatment Diabetic Retinopathy Study) classification systems are most widely used. [8]
• Background Retinopathy (R1): Microaneurysms, dot/blot haemorrhages, hard exudates – indicates mild vascular damage.
• Pre-Proliferative (R2): Cotton wool spots (retinal nerve fibre layer infarcts indicating ischaemia), venous beading, intraretinal microvascular abnormalities (IRMA) – high-risk features for progression.
• Proliferative (R3): Neovascularisation at disc (NVD) or elsewhere (NVE), pre-retinal/vitreous haemorrhage – requires urgent treatment.
• Maculopathy (M1): Retinal thickening or exudates within 1 disc diameter of the foveal centre – main cause of moderate vision impairment.
• Risk Factors: Duration of diabetes (strongest predictor), poor glycaemic control (elevated HbA1c), hypertension, dyslipidaemia, nephropathy, pregnancy, ethnicity (South Asian, African-Caribbean). [9,10]
• Treatment Modalities: Systemic optimisation, anti-VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab), pan-retinal photocoagulation, vitrectomy surgery.
• Evidence Base: Landmark trials (DCCT, UKPDS, DRS, ETDRS, Protocol T) demonstrate benefit of intensive glycaemic control and targeted retinal interventions. [11,12,13]

Clinical Pearls

"Silent Until Advanced": Early diabetic retinopathy is asymptomatic. Symptomatic disease often indicates advanced pathology. Screening is the only reliable detection method for early disease.

"Cotton Wool Spots Signal Ischaemia": The appearance of cotton wool spots (retinal nerve fibre layer infarctions) signals transition to pre-proliferative disease and indicates significant retinal ischaemia with high progression risk.

"Neovascularisation = Fragility": New vessels in proliferative disease lack normal structural integrity and readily bleed into vitreous space, causing sudden profound vision loss.

"Central vs Peripheral Vision Loss": Maculopathy predominantly affects central vision (reading, facial recognition, driving), while proliferative disease threatens peripheral and global vision through vitreous haemorrhage or tractional detachment.

"The 4:2:1 Rule": In severe NPDR, the 4-2-1 rule predicts high progression risk: severe haemorrhages in all 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant.

"Rapid HbA1c Reduction Paradox": Abrupt intensive glycaemic control can paradoxically worsen retinopathy short-term (treatment-induced neuropathy of diabetes phenomenon), necessitating close ophthalmological monitoring during aggressive diabetes management. [14]

Why This Matters Clinically

Diabetic retinopathy exemplifies the critical importance of preventive medicine and systematic screening in chronic disease management. With timely detection and evidence-based intervention, severe visual loss is preventable in the vast majority of patients. Pan-retinal photocoagulation reduces severe visual loss risk by more than 50% in proliferative disease. [15] Anti-VEGF therapy has revolutionised diabetic macular oedema treatment, with superior visual outcomes compared to historical laser monotherapy. [16,17] The condition also serves as a visible biomarker for systemic microvascular disease, with presence and severity correlating with nephropathy, neuropathy, and cardiovascular risk.

---

2. Epidemiology

Global Prevalence and Incidence

Overall Burden

The global prevalence of diabetic retinopathy among individuals with diabetes mellitus is approximately 35% (95% CI: 33.2-36.9%), with significant regional variation. [7] Approximately 7% of diabetics have sight-threatening retinopathy, defined as proliferative diabetic retinopathy or diabetic macular oedema. [7]

Systematic reviews estimate the following prevalence by DR severity among diabetic populations: [18]

• Any DR: 34.6% (range 20-50% by region)
• Proliferative DR: 6.96%
• Diabetic Macular Oedema: 6.81%
• Vision-threatening DR: 10.2%

Incidence Rates

Longitudinal studies demonstrate the following 4-year incidence rates among patients with diabetes: [18]

• Development of any DR: 7.8-34% (depending on baseline status)
• Progression to proliferative DR: 3.4-9.3%
• Development of DMO: 4.2-8.9%

Type 1 vs Type 2 Diabetes

Type 1 Diabetes: Nearly 100% of patients with Type 1 diabetes develop some degree of retinopathy after 20 years' duration. [19] Approximately 60% develop proliferative disease without screening and treatment interventions.

Type 2 Diabetes: Approximately 20-30% have retinopathy at diagnosis (reflecting prolonged pre-diagnostic hyperglycaemia). [10] The prevalence increases progressively with disease duration.

Leading Cause of Blindness

DR is the leading cause of blindness in working-age adults (20-74 years) in developed countries. [2] It accounts for approximately 12% of all new cases of blindness in developed nations. In low- and middle-income countries, untreated cataract remains the leading cause, but DR burden is rising with increasing diabetes prevalence.

Geographic Variation

Prevalence varies by region and ethnicity:

• Highest rates: African-Caribbean, South Asian, Hispanic/Latino, Indigenous populations
• Ethnic disparities: South Asian populations demonstrate 2-3 fold higher prevalence compared to European populations with similar diabetes duration and control. [9]

Risk Factors

Non-Modifiable Risk Factors

Modifiable Risk Factors

Protective Factors

• Intensive glycaemic control from early diabetes diagnosis (metabolic memory effect) [11]
• Blood pressure optimisation [21]
• Lipid management with fenofibrate (modest DMO reduction) [27]
• Regular screening enabling early detection and treatment

Temporal Trends

The introduction of systematic screening programmes (e.g., NHS Diabetic Eye Screening Programme in England, 2003) has significantly reduced blindness from DR. Between 2000-2020, DR-related blindness registrations decreased by approximately 50% in countries with established screening. [28]

---

3. Pathophysiology

Overview: From Hyperglycaemia to Vision Loss

Diabetic retinopathy represents a progressive microvascular disease initiated by chronic hyperglycaemia and perpetuated by complex biochemical, haemodynamic, and inflammatory cascades. The pathological sequence progresses through distinct phases:

1. Hyperglycaemia-induced metabolic dysfunction
2. Retinal capillary damage (pericyte loss, endothelial dysfunction)
3. Breakdown of blood-retinal barrier (increased vascular permeability)
4. Retinal ischaemia (capillary occlusion, non-perfusion)
5. Pathological neovascularisation (VEGF-mediated angiogenesis)
6. Structural complications (vitreous haemorrhage, tractional detachment)

Molecular Mechanisms of Hyperglycaemic Damage

1. Polyol Pathway Activation

Chronic hyperglycaemia drives intracellular glucose into the polyol pathway, where aldose reductase converts glucose to sorbitol. Sorbitol accumulation causes:

• Osmotic stress within retinal cells
• NADPH depletion (reducing antioxidant capacity)
• Pericyte damage and capillary basement membrane thickening [29]

2. Advanced Glycation End Products (AGEs)

Non-enzymatic glycation of proteins and lipids produces AGEs, which:

• Cross-link structural proteins (basement membrane thickening)
• Bind to RAGE (receptor for AGE), triggering inflammatory signalling (NF-κB activation)
• Increase oxidative stress and vascular permeability [29,30]

3. Protein Kinase C (PKC) Activation

Hyperglycaemia activates diacylglycerol (DAG), which stimulates PKC, particularly the β-isoform. PKC activation induces:

• Increased vascular permeability (VEGF upregulation)
• Altered retinal blood flow
• Basement membrane thickening
• Leukocyte adhesion and vascular occlusion [29]

4. Oxidative Stress

Mitochondrial superoxide overproduction occurs in hyperglycaemic conditions, leading to:

• Direct endothelial and pericyte damage
• Activation of the above pathways (AGE, PKC, polyol)
• DNA damage and cellular dysfunction [30]

5. Inflammation

Chronic low-grade inflammation characterises DR pathogenesis:

• Elevated inflammatory cytokines (IL-6, IL-8, TNF-α, MCP-1)
• Leukocyte adhesion to retinal capillaries (leukostasis)
• Microvascular occlusion and endothelial damage [30]

Structural Changes in the Diabetic Retina

Early Vascular Changes (Background Retinopathy)

Retinal Ischaemia (Pre-Proliferative Retinopathy)

Progressive microvascular occlusion leads to retinal ischaemia, manifesting as:

The "4-2-1 Rule" identifies severe NPDR at high risk of progression:

• Severe haemorrhages/microaneurysms in 4 quadrants, OR
• Venous beading in ≥2 quadrants, OR
• IRMA in ≥1 quadrant [8]

Pathological Neovascularisation (Proliferative Retinopathy)

Retinal ischaemia triggers a hypoxia-driven angiogenic response:

VEGF (Vascular Endothelial Growth Factor): The central mediator

• Hypoxic retina (especially photoreceptors and Müller cells) upregulates Hypoxia-Inducible Factor (HIF)
• HIF transcriptionally activates VEGF gene expression
• VEGF induces endothelial cell proliferation, migration, and new vessel formation [32]

Neovascular Characteristics:

• Neovascularisation at Disc (NVD): New vessels on or within 1 disc diameter of the optic nerve head
• Neovascularisation Elsewhere (NVE): New vessels elsewhere on the retina
• Fragile Architecture: New vessels lack proper pericyte coverage, tight junctions, and basement membrane – making them structurally weak and prone to haemorrhage
• Fibrovascular Proliferation: New vessels grow with fibrous tissue scaffold, which contracts and causes tractional forces on the retina [33]

Diabetic Macular Oedema (DMO)

DMO results from breakdown of the blood-retinal barrier at the macula:

Mechanisms:

1. VEGF-mediated permeability: VEGF disrupts endothelial tight junctions (particularly occludin, claudin, ZO-1 proteins), increasing capillary permeability [32]
2. Inflammatory mediators: IL-6, ICAM-1, VEGF, prostaglandins contribute to barrier breakdown
3. Fluid accumulation: Extracellular fluid accumulates in the retina (particularly outer plexiform and inner nuclear layers)
4. Cystoid spaces: Chronic oedema leads to cystoid cavities within the retina

Clinical Classification:

• Focal DMO: Leakage from identifiable microaneurysms; circinate hard exudate rings
• Diffuse DMO: Generalised capillary leakage; widespread retinal thickening
• Ischaemic maculopathy: Capillary non-perfusion affecting the macula; poor visual prognosis despite treatment [4]

OCT Features: Optical coherence tomography demonstrates:

• Increased central subfield thickness (CST > 300 μm)
• Intraretinal cystoid spaces
• Subretinal fluid (in some cases)
• Disorganisation of retinal inner layers (DRIL) – poor prognostic marker [34]

Role of the Vitreous

The posterior vitreous provides a scaffold for neovascular proliferation:

• New vessels grow along the posterior vitreous surface
• Vitreous detachment creates traction, causing:
  • "Vitreous haemorrhage: Rupture of fragile new vessels"
  • "Tractional retinal detachment: Fibrovascular membranes contract, pulling the retina from the RPE"
• Incomplete or anomalous vitreous detachment increases complication risk [33]

Neurodegeneration in Diabetic Retinopathy

Emerging evidence demonstrates that DR is not purely a vascular disease – neurodegeneration precedes clinically visible vascular changes:

• Retinal ganglion cell apoptosis occurs early in diabetes
• Glial cell dysfunction (Müller cells, astrocytes) impairs retinal homeostasis
• Neuronal thinning detectable on OCT before visible retinopathy
• Electrophysiological abnormalities (reduced multifocal ERG amplitude) [35]

This neurovascular paradigm suggests DR begins as a neurodegenerative condition, with secondary vascular manifestations.

---

4. Classification Systems

UK National Screening Committee (NSC) Grading System

The NHS Diabetic Eye Screening Programme uses a simplified grading system for population-level screening:

Retinopathy Grading (R0-R3)

Maculopathy Grading (M0-M1)

The NHS system uses digital fundus photography (mydriatic or non-mydriatic) capturing:

• 2 fields per eye (disc-centred and macula-centred), OR
• Single 45° field capturing both disc and macula

[Source: NHS Diabetic Eye Screening Programme Guidelines]

ETDRS (Early Treatment Diabetic Retinopathy Study) Classification

The ETDRS severity scale provides granular grading based on 7-field stereoscopic fundus photography and is used in research and clinical trials. [8]

ETDRS Levels

Diabetic Macular Oedema (DMO) – ETDRS Definition

Clinically Significant Macular Oedema (CSME): Any of the following:

1. Retinal thickening ≤500 μm from foveal centre
2. Hard exudates ≤500 μm from foveal centre with adjacent retinal thickening
3. Retinal thickening ≥1 disc area, any part of which is ≤1 disc diameter from foveal centre

[Modern OCT-based definitions have largely replaced clinical CSME criteria in practice.]

International Clinical Diabetic Retinopathy Disease Severity Scale

Simplified scale for international use:

OCT-Based DMO Classification

Modern optical coherence tomography (OCT) enables quantitative assessment:

---

5. Clinical Presentation

Symptoms

Diabetic retinopathy is characteristically asymptomatic in early stages. Symptoms develop only when significant macular involvement or complications occur:

By Disease Stage

Signs on Examination

Visual Acuity

• Early DR (R0-R1): Normal
• Maculopathy: Reduced (often 6/12 to 6/60)
• Severe PDR complications: Profound loss (counting fingers to perception of light)

Pupillary Examination

• Usually normal unless advanced disease with afferent pupillary defect (APD) due to extensive retinal damage

Fundoscopy / Dilated Ophthalmoscopy

Direct and indirect ophthalmoscopy findings:

Background Retinopathy (R1)

• Microaneurysms: Tiny, discrete red dots (earliest clinical sign)
• Dot haemorrhages: Deeper retinal haemorrhages (round)
• Blot haemorrhages: Larger, deeper haemorrhages
• Hard exudates: Yellow, waxy deposits (lipid); well-demarcated; may form circinate (ring) patterns

Pre-Proliferative Retinopathy (R2)

• Cotton wool spots: White/grey, fluffy patches (nerve fibre layer infarcts)
• Venous beading: Irregular, sausage-like venous calibre
• Venous loops/duplication: Abnormal venous tortuosity
• IRMA: Fine, irregular red lines within the retina (intraretinal shunt vessels)
• Multiple/large deep haemorrhages: ("dark blot" haemorrhages in all quadrants)
• Arterial narrowing: Generalised or focal

Proliferative Retinopathy (R3)

• Neovascularisation at Disc (NVD): Fine new vessels on or near optic disc
• Neovascularisation Elsewhere (NVE): New vessels on retina (often along vascular arcades)
• Pre-retinal haemorrhage: "Boat-shaped" haemorrhage anterior to retina, below vitreous
• Vitreous haemorrhage: Diffuse red haze obscuring fundal view
• Fibrous tissue proliferation: White/grey membranes; may cause vascular distortion
• Tractional retinal detachment: Elevated retina; loss of red reflex; retinal folds

Maculopathy (M1)

• Retinal thickening: Loss of foveal reflex; grey discolouration
• Macular hard exudates: Circinate exudates near or at fovea
• Macular haemorrhages: Blood near foveal centre
• Cystoid macular oedema (on slit lamp biomicroscopy/OCT): "Honeycomb" appearance

Slit Lamp Biomicroscopy

• Essential for macular assessment: Stereoscopic view with high magnification
• +90D or +78D lens: Enables detailed posterior pole examination
• Rubeosis iridis detection: Abnormal blood vessels on iris surface (indicates severe ischaemia and neovascular glaucoma risk)

Intraocular Pressure (IOP)

• Usually normal in uncomplicated DR
• Elevated in neovascular glaucoma (rubeosis iridis blocking trabecular meshwork)

---

6. Investigations

Screening and Initial Assessment

1. Digital Fundus Photography (Mainstay of Screening)

Method:

• Mydriatic: Pupils dilated with tropicamide 1% or phenylephrine 2.5%
• Non-mydriatic: Modern wide-field cameras enable imaging through undilated pupils
• Standard protocol: 2-field imaging per eye (macula-centred and disc-centred) or single-field capturing both

Grading:

• Images graded by trained screeners using NSC criteria (R0-R3, M0-M1)
• Quality assurance: internal and external validation

Sensitivity/Specificity:

• Sensitivity for referable DR: 80-95%
• Specificity: > 90%

Advantages: Population-level screening; relatively low cost; remote grading possible

Limitations: Cannot replace ophthalmoscopy for diagnostic detail; image quality issues (cataracts, media opacity)

[Source: NHS Diabetic Eye Screening Programme]

2. Visual Acuity Testing

• Standard: Snellen chart (6/6, 6/12, 6/60, etc.) or ETDRS logMAR chart (research standard)
• Pinhole test: If reduced acuity, to distinguish refractive error from pathological visual loss

3. Intraocular Pressure (IOP)

• Goldmann applanation tonometry (gold standard) or non-contact tonometry
• Detect neovascular glaucoma (IOP > 30 mmHg in acute cases)

Ophthalmology Clinic Assessment

4. Slit Lamp Biomicroscopy with Fundal Lenses

• +90D, +78D non-contact lenses or contact lenses (Goldmann 3-mirror, Volk quadraspheric)
• Essential for detailed macular examination and subtle neovascularisation detection
• Assessment of rubeosis iridis (iris neovascularisation)

5. Optical Coherence Tomography (OCT)

Principle: Non-invasive, high-resolution cross-sectional retinal imaging using interferometry.

Role in DR:

• Gold standard for DMO assessment: Quantifies central subfield thickness (CST), macular volume
• Structural detail: Intraretinal cysts, subretinal fluid, DRIL, epiretinal membrane, vitreomacular traction
• Treatment monitoring: Serial OCT tracks response to anti-VEGF or laser therapy

Key Parameters:

• CST (central subfield thickness): Normal less than 300 μm; DMO typically > 320 μm
• DRIL: Extent predicts visual prognosis [34]
• Ellipsoid zone integrity: Disruption indicates photoreceptor damage (poor visual prognosis)

OCT Angiography (OCTA): Emerging technology enabling vessel mapping without dye injection; useful for:

• Foveal avascular zone (FAZ) assessment
• Neovascularisation detection
• Capillary non-perfusion mapping

Limitations: Cannot image through dense vitreous haemorrhage or significant media opacity

6. Fluorescein Angiography (FFA)

Principle: Intravenous sodium fluorescein dye; serial fundus photographs capture dye transit and leakage.

Indications in DR:

• DMO characterisation: Distinguish focal vs diffuse leakage; guide laser treatment
• Capillary non-perfusion mapping: Identify ischaemic retina (areas of non-filling)
• Neovascularisation confirmation: New vessels demonstrate hyperfluorescence and leakage
• Differentiating DR from other retinopathies (e.g., retinal vein occlusion)

Phases:

• Early arteriovenous (10-20 sec): Vessel filling
• Mid-phase (1-5 min): Capillary filling; leakage starts
• Late-phase (5-10 min): Diffuse leakage from abnormal vessels; pooling in cystoid spaces

FFA Findings:

• Microaneurysms: Pinpoint hyperfluorescence
• Capillary non-perfusion: Dark (non-filling) areas
• Neovascularisation: Lacy hyperfluorescence with late leakage
• Macular oedema: Petaloid (flower-petal) late staining pattern

Adverse Effects: Nausea (common, 5-10%), anaphylaxis (rare, 1:200,000)

Contraindications: Pregnancy (relative); known severe allergy to fluorescein

7. Ultrawide-Field Imaging

• Optos or similar platforms: Capture up to 200° retinal view (vs standard 30-50°)
• Advantages: Detects peripheral neovascularisation; enhances DR severity grading [36]
• Increasingly used in research and tertiary centres

8. B-Scan Ultrasonography

• Indication: Dense vitreous haemorrhage obscuring fundal view
• Purpose: Assess for tractional retinal detachment, posterior vitreous detachment status
• Essential for surgical planning if vitrectomy contemplated

---

7. Management

Overarching Principles

1. Prevention through screening: Early detection before symptoms
2. Systemic risk factor optimisation: Glycaemic control, blood pressure, lipids
3. Timely referral: Sight-threatening disease requires urgent ophthalmology assessment
4. Evidence-based interventions: Anti-VEGF, laser photocoagulation, vitreoretinal surgery
5. Long-term monitoring: DR can progress despite treatment; ongoing surveillance essential

Systemic Management (Foundation of All DR Management)

Glycaemic Control

Evidence: Intensive glycaemic control reduces DR incidence and progression:

• DCCT (Diabetes Control and Complications Trial): Intensive insulin therapy (target HbA1c ~7% / 53 mmol/mol) reduced DR incidence by 76% and progression by 54% in Type 1 diabetes. [11]
• UKPDS (UK Prospective Diabetes Study): Intensive control in Type 2 diabetes reduced DR progression by 25%. [12]
• EDIC (Epidemiology of Diabetes Interventions and Complications): Long-term follow-up demonstrated "metabolic memory" – early intensive control confers sustained benefit decades later. [37]

Target:

• HbA1c less than 53 mmol/mol (7%) for most patients with diabetes
• Individualise based on hypoglycaemia risk, life expectancy, comorbidities

Caution: Rapid HbA1c reduction (> 2-3% within 3-6 months) can paradoxically worsen DR short-term (early worsening phenomenon / treatment-induced retinopathy). Mechanism unclear; may relate to rapid haemodynamic changes. Close ophthalmological monitoring required during aggressive glycaemic optimisation. [14]

Blood Pressure Control

Evidence:

• UKPDS: Tight BP control (less than 150/85 mmHg) reduced DR progression by 34% and reduced risk of vision loss. [21]
• Meta-analyses confirm BP lowering reduces DR incidence and progression. [38]

Target:

• less than 130/80 mmHg for patients with diabetes (current guidelines)
• ACE inhibitors or ARBs may confer additional microvascular benefit beyond BP lowering alone

Lipid Management

Evidence:

• FIELD Study (Fenofibrate Intervention and Event Lowering in Diabetes): Fenofibrate reduced need for laser photocoagulation by 31% (primarily through DMO reduction). [27]
• Statins: Reduce cardiovascular risk; modest benefit for DR in some studies

Target:

• Statin therapy if cardiovascular risk factors present
• Fenofibrate may be considered in patients with dyslipidaemia and DMO (specialist decision)

Other Systemic Factors

• Smoking cessation: Reduces microvascular disease progression
• Anaemia correction: Optimise haemoglobin if anaemic
• Pregnancy planning: Pre-conception screening; increased monitoring during pregnancy

Screening and Monitoring

Screening Frequency by DR Status

Pregnancy: Screen at booking, 16-20 weeks, 28 weeks, and postnatal (retinopathy can progress rapidly during pregnancy). [39]

Type 1 diabetes: Begin screening 5 years after diagnosis (retinopathy rare before puberty).

Type 2 diabetes: Screen at diagnosis (may have had undiagnosed diabetes for years).

Treatment by Disease Stage

R0 and R1: No Retinopathy or Background Retinopathy

Management:

• Annual screening
• Systemic optimisation: HbA1c, BP, lipids
• Patient education: importance of screening adherence and systemic control
• No ophthalmic intervention required

R2: Pre-Proliferative Retinopathy

Management:

• Refer to ophthalmology (routine, within 6 weeks)
• Ophthalmology assessment: confirm grading, FFA if indicated, assess ischaemia extent
• Close monitoring: 3-6 monthly review (depending on severity and risk factors)
• Systemic optimisation: intensify HbA1c and BP control
• Consider PRP if very severe NPDR or high-risk features (specialist decision)

No immediate laser treatment unless high-risk features; observation often appropriate

R3: Proliferative Diabetic Retinopathy (PDR)

Management: Sight-threatening disease; requires urgent ophthalmology referral (within 2 weeks).

Treatment Options for PDR

1. Pan-Retinal Photocoagulation (PRP)

Mechanism:

• Laser burns destroy peripheral ischaemic retina
• Reduces metabolic oxygen demand
• Decreases VEGF production
• Promotes regression of neovascularisation

Landmark Trial: Diabetic Retinopathy Study (DRS): PRP reduced severe visual loss by > 50% in high-risk PDR. [15]

Technique:

• 1200-2000 burns applied to peripheral retina (sparing macula and major vessels)
• Argon green or multispot pattern laser (modern)
• Usually performed in 2-3 sessions (single-session PRP possible)
• Burns: 200-500 μm spot size, 0.1-0.2 sec duration, moderate intensity

Indications:

• High-risk PDR: NVD ≥⅓ disc area, any NVD with vitreous haemorrhage, NVE ≥½ disc area with vitreous haemorrhage
• Severe NPDR (if high risk of progression or poor follow-up likely)

Adverse Effects:

• Peripheral visual field loss (unavoidable)
• Reduced night vision
• Transient macular oedema (can worsen DMO short-term)
• Pain during treatment (usually tolerable; sub-Tenon's anaesthesia if needed)

Outcomes: Neovascularisation regression in 70-80% cases; stabilisation of vision in majority

2. Anti-VEGF Therapy for PDR

Mechanism: Inhibit VEGF, reducing neovascularisation and vascular permeability

Agents:

• Ranibizumab (Lucentis): Fab fragment of anti-VEGF-A antibody
• Aflibercept (Eylea): Fusion protein (VEGF receptor decoy); binds VEGF-A, VEGF-B, PlGF
• Bevacizumab (Avastin): Off-label; full anti-VEGF-A antibody; cost-effective alternative

Evidence: Protocol S (2015): Ranibizumab non-inferior to PRP for PDR visual outcomes; better visual acuity at 2 years; less peripheral field loss. [40]

Indications:

• PDR (alternative to PRP, especially if concurrent DMO)
• Adjunct to PRP (reduce neovascularisation before laser)
• Pre-operative in severe PDR before vitrectomy (reduce bleeding risk)

Regimen: Monthly injections initially; then PRN (as needed) based on disease activity

Advantages over PRP:

• No peripheral field loss
• Better visual acuity outcomes (on average)
• Simultaneous DMO treatment

Disadvantages:

• Requires frequent injections (treatment burden)
• High cost (except bevacizumab off-label)
• Risk of rebound if treatment stopped

Combined PRP + Anti-VEGF

Some centres use combination therapy:

• Anti-VEGF to regress neovascularisation quickly
• PRP for long-term ischaemia reduction
• May reduce injection burden

M1: Diabetic Macular Oedema (DMO)

Management: Urgent ophthalmology referral (within 6 weeks).

Treatment Options for DMO

1. Anti-VEGF Intravitreal Injections (First-Line for Centre-Involving DMO)

Evidence:

• DRCR.net Protocol T: Compared aflibercept, bevacizumab, and ranibizumab for CI-DMO. Aflibercept superior when baseline VA less than 69 letters (worse than ~6/12); all three equivalent if better baseline VA. [16]
• VIVID and VISTA: Aflibercept superior to laser for DMO. [41]
• RESTORE: Ranibizumab superior to laser. [42]

Agents and Regimens:

Technique:

• Intravitreal injection under topical anaesthesia (proxymetacaine drops)
• Aseptic technique: povidone-iodine 5% to conjunctiva, sterile drape
• Injection site: 3.5-4 mm posterior to limbus (pseudophakic/phakic)

Outcomes:

• Mean visual acuity gain: +5 to +10 letters (1-2 Snellen lines)
• Anatomical improvement: CST reduction 100-150 μm
• ~40% of patients gain ≥15 letters (3 lines)

Adverse Effects:

• Endophthalmitis (rare: ~1:2000-5000 injections)
• Intraocular haemorrhage (common, self-limiting)
• Retinal detachment (very rare)
• Increased IOP (transient spike; chronic elevation in some patients with repeated injections)
• Systemic thromboembolic events (theoretical risk; unclear causality)

Treatment Burden: Major limitation; requires frequent hospital visits and repeated injections. Patient compliance critical for success.

2. Macular Laser Photocoagulation

Historical Gold Standard: ETDRS demonstrated macular laser reduces moderate vision loss by 50% in clinically significant macular oedema. [13]

Current Role: Largely superseded by anti-VEGF for CI-DMO; may still be used for:

• Focal DMO (leaking microaneurysms away from foveal centre)
• Combination with anti-VEGF (may reduce injection burden)
• Persistent DMO despite anti-VEGF (salvage)

Technique:

• Focal laser: Direct treatment to leaking microaneurysms (50-100 μm spots)
• Grid laser: Mild burns to areas of diffuse leakage/oedema (sparing fovea)

Outcome: Stabilises vision; rarely improves acuity

3. Intravitreal Corticosteroids

Agents:

• Dexamethasone intravitreal implant (Ozurdex): 0.7 mg sustained-release; duration ~4-6 months
• Fluocinolone acetonide implant (Iluvien): 0.19 mg; duration ~36 months

Indications:

• Persistent DMO despite anti-VEGF therapy
• Pseudophakic patients (cataracts less concerning)
• Chronic DMO (Iluvien for long-term control)

Mechanism: Reduce inflammation, vascular permeability, VEGF expression

Adverse Effects:

• Cataract (almost universal in phakic patients)
• IOP elevation (30-40% patients; may require drops or surgery)
• Endophthalmitis (rare)

Outcomes: Effective for DMO; ~50% gain ≥15 letters; useful second-line option

Advanced Complications: Vitrectomy Surgery

Indications:

• Non-clearing vitreous haemorrhage (> 2-3 months)
• Tractional retinal detachment (threatening or involving macula)
• Combined tractional-rhegmatogenous retinal detachment
• Severe fibrovascular proliferation
• Dense premacular haemorrhage

Procedure: Pars plana vitrectomy (PPV)

• Remove vitreous gel
• Peel fibrovascular membranes (membrane dissection)
• Endolaser photocoagulation
• Gas or silicone oil tamponade (if retinal detachment)

Outcomes:

• Anatomical success: 80-90% (retinal reattachment)
• Visual outcome: Variable; depends on macular status and pre-operative vision
• Better if surgery before macular detachment

Complications:

• Cataract (almost universal; may require subsequent cataract surgery)
• Recurrent vitreous haemorrhage
• Retinal detachment recurrence
• Raised IOP (especially if silicone oil used)

---

8. Complications

Ocular Complications

Systemic Associations

Diabetic retinopathy correlates with other microvascular and macrovascular diabetic complications:

• Diabetic Nephropathy: Strong association; albuminuria and reduced eGFR correlate with DR severity. [23]
• Diabetic Neuropathy: Peripheral and autonomic neuropathy often coexist.
• Cardiovascular Disease: DR predicts cardiovascular events; shared microvascular pathophysiology.
• Stroke: DR severity correlates with stroke risk.

The presence of retinopathy should prompt comprehensive microvascular and cardiovascular risk assessment.

---

9. Prognosis and Outcomes

Natural History (Untreated)

With Treatment

Prognostic Factors for Poor Visual Outcome

Poor Prognosis Indicators:

• Baseline poor vision (less than 6/60)
• Macular ischaemia (non-perfused fovea)
• DRIL (disorganisation of retinal inner layers) on OCT [34]
• Chronic DMO (> 6 months untreated)
• Severe PDR with tractional detachment
• Concurrent systemic disease (severe nephropathy, cardiovascular disease)

Good Prognosis Indicators:

• Early detection (pre-symptomatic)
• Good baseline vision (≥6/12)
• Timely treatment
• Good systemic control (HbA1c, BP)

---

10. Evidence and Guidelines

Key Clinical Trials

Key Guidelines

---

11. Exam Scenarios and Clinical Vignettes

Vignette 1: Background Retinopathy

Stem: A 55-year-old man with Type 2 diabetes (15 years' duration) attends routine screening. Fundus photography demonstrates multiple microaneurysms, scattered dot haemorrhages, and a few hard exudates temporal to the macula in both eyes. No cotton wool spots or new vessels visible. Visual acuity 6/6 OU. What is the appropriate management?

Answer: This patient has R1 (Background Diabetic Retinopathy) in both eyes. Management includes:

1. Continue annual screening
2. Optimise systemic control: Review HbA1c (target less than 53 mmol/mol), blood pressure (less than 130/80 mmHg), lipids
3. Patient education: Emphasise importance of screening adherence and glycaemic control
4. No ophthalmology referral required at this stage

Key Point: R1 is low-risk; systemic optimisation is the primary intervention.

---

Vignette 2: Pre-Proliferative Retinopathy

Stem: A 62-year-old woman with Type 2 diabetes attends screening. Fundus photographs show multiple cotton wool spots, venous beading in two quadrants, and IRMA in one quadrant. No neovascularisation detected. What is the diagnosis and management?

Answer: This patient has R2 (Pre-Proliferative Diabetic Retinopathy) with high-risk features for progression (meets "4-2-1 rule" criteria).

Management:

1. Refer to ophthalmology (routine, within 6 weeks)
2. Ophthalmology assessment: Confirm grading; consider fluorescein angiography to assess ischaemia extent
3. Close monitoring (3-6 monthly) for progression to proliferative disease
4. Intensify systemic control
5. Consider PRP if very high risk or progression noted

Key Point: Cotton wool spots signal retinal ischaemia – high progression risk requires ophthalmology review.

---

Vignette 3: Proliferative Retinopathy

Stem: A 48-year-old man with Type 1 diabetes (25 years' duration) presents to his GP with sudden onset of floaters and reduced vision in his right eye over 2 days. Visual acuity: 6/60 OD, 6/9 OS. What is the likely diagnosis and immediate management?

Answer: Vitreous haemorrhage secondary to proliferative diabetic retinopathy (R3).

Immediate Management:

1. Urgent ophthalmology referral (same day if possible, certainly within 48 hours)
2. Avoid aspirin/anticoagulants if safe to do so (discuss with ophthalmology/cardiology)
3. B-scan ultrasonography (by ophthalmology) to rule out tractional retinal detachment
4. Examine fellow eye: Assess for bilateral PDR

Ophthalmology Management:

• If vitreous haemorrhage alone: Observe 2-3 months (may clear spontaneously)
• If non-clearing or bilateral or tractional detachment: Vitrectomy
• Once view clears: PRP laser or anti-VEGF to treat underlying proliferative disease

Key Point: Sudden floaters/vision loss = vitreous haemorrhage until proven otherwise. Requires urgent assessment.

---

Vignette 4: Diabetic Macular Oedema

Stem: A 59-year-old woman with Type 2 diabetes attends routine screening. She reports gradual blurring of central vision over 3 months. Visual acuity 6/18 OU. Fundus photography shows hard exudates within one disc diameter of the fovea bilaterally. OCT demonstrates central subfield thickness 420 μm OU (normal less than 300 μm) with intraretinal cysts. What is the diagnosis and management?

Answer: Diabetic Macular Oedema (M1, Centre-Involving DMO) bilaterally.

Management:

1. Urgent ophthalmology referral (within 6 weeks, ideally sooner given bilateral symptomatic disease)
2. First-line treatment: Intravitreal anti-VEGF injections (aflibercept, ranibizumab, or bevacizumab)
   • Likely regimen: Monthly injections initially (e.g., 5 monthly aflibercept), then PRN or treat-and-extend
3. Systemic optimisation: Review HbA1c, BP, lipids
4. Serial OCT monitoring: Track anatomical response (CST reduction)

Expected Outcome: Vision stabilisation or improvement; CST reduction to less than 350 μm

Key Point: Centre-involving DMO with visual symptoms requires anti-VEGF therapy (superior to laser for central disease). [16,17]

---

Vignette 5: Neovascular Glaucoma

Stem: A 67-year-old man with longstanding poorly controlled Type 2 diabetes presents to A&E with severe right eye pain, redness, and vision loss. Examination: visual acuity counting fingers OD, 6/12 OS; right eye injected, hazy cornea, fixed mid-dilated pupil, IOP 52 mmHg OD. Slit lamp shows new vessels on the iris surface (rubeosis iridis). What is the diagnosis and immediate management?

Answer: Neovascular Glaucoma (secondary to severe diabetic retinopathy with retinal ischaemia).

Immediate Management:

1. Medical IOP reduction:
   • Topical: Timolol 0.5%, dorzolamide 2%, apraclonidine 1%
   • Oral: Acetazolamide 500 mg
   • IV: Mannitol 20% if IOP remains > 50 mmHg
2. Analgesia: Oral or IV analgesia (severe pain)
3. Urgent ophthalmology review (same day)
4. Investigate underlying ischaemia: Dilated fundoscopy (if cornea clears) or B-scan to assess for PDR, vitreous haemorrhage, tractional detachment

Ophthalmology Management:

• Pan-retinal photocoagulation (PRP) or intravitreal anti-VEGF to treat retinal ischaemia and regress iris neovascularisation
• Drainage surgery (trabeculectomy + antimetabolite or glaucoma drainage device) if medical treatment insufficient
• Cycloablation (destroy ciliary body to reduce aqueous production) if eye non-salvageable

Prognosis: Guarded; visual prognosis poor if advanced disease. Prevention through timely DR screening and treatment is critical.

Key Point: Rubeosis iridis = severe retinal ischaemia. Treat underlying ischaemia urgently with PRP or anti-VEGF to prevent irreversible glaucoma.

---

12. Triage and Referral Pathways

---

13. Patient Counselling and Education

For Patients: What is Diabetic Retinopathy?

Diabetic retinopathy is damage to the blood vessels in the back of your eye (the retina) caused by diabetes. High blood sugar over time damages these tiny vessels, which can leak fluid, become blocked, or grow abnormally.

Why is screening important? Early diabetic retinopathy has no symptoms. You won't notice any vision changes until the disease is advanced. Annual eye screening (a photograph of the back of your eye) can detect problems early, when treatment is most effective and can prevent vision loss.

What happens if I have diabetic retinopathy?

• Mild disease (R1): Continue screening and improve blood sugar/blood pressure control. No treatment needed yet.
• More advanced disease (R2, R3, M1): You'll be referred to an eye specialist (ophthalmologist) for further tests and possible treatment.

Treatments:

• Laser treatment: A focused beam of light seals leaking vessels or destroys abnormal new vessels. Prevents severe vision loss.
• Eye injections (Anti-VEGF): Medicine injected into the eye to reduce swelling and stop abnormal vessel growth. Very effective for macular swelling.
• Surgery (Vitrectomy): If there is bleeding or retinal detachment, surgery may be needed to clear blood and repair the retina.

What can I do?

1. Control your blood sugar: This is the most important thing. Good control prevents retinopathy or slows progression.
2. Control your blood pressure: High blood pressure worsens retinopathy.
3. Attend all eye screening appointments: Don't miss them. Early detection saves sight.
4. Stop smoking: Smoking damages blood vessels.
5. Report vision changes: If your vision suddenly changes (floaters, blurriness, loss), seek urgent medical help.

Key Message: "Diabetic retinopathy is preventable and treatable if caught early. Attend your annual eye screening – it could save your sight."

---

14. Quality Markers and Audit Standards

---

15. Historical Context and Milestones

---

16. Future Directions and Emerging Therapies

Artificial Intelligence (AI) and Automated Screening

• Deep learning algorithms (e.g., Google DeepMind, IDx-DR) demonstrate sensitivity/specificity > 90% for referable DR detection
• Potential to expand screening access in low-resource settings
• Regulatory approval granted in some jurisdictions (FDA approved IDx-DR 2018)

Longer-Lasting Anti-VEGF Agents

• Faricimab (Vabysmo): Dual VEGF/Ang-2 inhibitor; demonstrated extended dosing intervals (up to 16 weeks) in clinical trials
• Port Delivery System (PDS): Implantable reservoir providing continuous ranibizumab release; refillable every 6 months

Neuroprotection

• Recognition of neurodegenerative component in DR drives research into neuroprotective therapies
• Potential agents: somatostatin analogues, dopamine agonists, antioxidants

Gene Therapy

• Experimental approaches targeting VEGF suppression or neuroprotection via viral vector delivery
• Long-term efficacy remains to be established

Non-Invasive Imaging

• OCT Angiography (OCTA): Dye-free vessel imaging; rapid assessment of capillary perfusion and neovascularisation
• Adaptive Optics: Cellular-level retinal imaging; research applications in early DR detection

---

17. References

1. Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021 Aug;12(8):1322-1325. doi: 10.1111/jdi.13480

2. Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149. doi: 10.1016/S2213-8587(18)30128-1

3. Attiku Y, Nittala MG, Velaga SB, et al. Comparison of diabetic retinopathy severity grading on ETDRS 7-field versus ultrawide-field assessment. Eye (Lond). 2023 Oct;37(14):2961-2967. doi: 10.1038/s41433-023-02445-8

4. Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023 Mar-Apr;68(2):147-174. doi: 10.1016/j.survophthal.2022.11.008

5. Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018 Oct;125(10):1608-1622. doi: 10.1016/j.ophtha.2018.04.007

6. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002

7. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909

8. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):786-806.

9. Tsui CK, Hu A, Li Y, et al. Prevalence, incidence, and risk factors of diabetic retinopathy and macular edema in patients with early and late-onset type 2 diabetes mellitus. J Diabetes Investig. 2025 Jul;16(7):908-919. doi: 10.1111/jdi.70027

10. Faselis C, Katsimardou A, Imprialos K, et al. Microvascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):117-124. doi: 10.2174/1570161117666190502103733

11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401

12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.

13. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):766-85.

14. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015 Jan;138(Pt 1):43-52. doi: 10.1093/brain/awu307

15. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981 Jul;88(7):583-600.

16. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022

17. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424

18. Medina-Ramirez SA, Soriano-Moreno DR, Tuco KG, et al. Prevalence and incidence of diabetic retinopathy in patients with diabetes of Latin America and the Caribbean: A systematic review and meta-analysis. PLoS One. 2024;19(3):e0296998. doi: 10.1371/journal.pone.0296998

19. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

20. Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3839-45. doi: 10.1167/iovs.07-1633

21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):703-13.

22. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996 Sep;114(9):1079-84.

23. Pearce I, Simó R, Lövestam-Adrian M, et al. Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes Obes Metab. 2019 Mar;21(3):467-478. doi: 10.1111/dom.13550

24. Rosenn B, Miodovnik M, Kranias G, et al. Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy. Am J Obstet Gynecol. 1992 Apr;166(4):1214-8.

25. Qiao Q, Keinänen-Kiukaanniemi S, Läara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997 Feb;50(2):153-8.

26. Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology. 2013 Mar;120(3):574-82. doi: 10.1016/j.ophtha.2012.08.029

27. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007 Nov 17;370(9600):1687-97. doi: 10.1016/S0140-6736(07)61607-9

28. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014 Feb 12;4(2):e004015. doi: 10.1136/bmjopen-2013-004015

29. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018 Jun 20;19(6):1816. doi: 10.3390/ijms19061816

30. Srejovic JV, Muric MD, Jakovljevic VL, et al. Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease-Interplay Between Inflammation and Oxidative Stress. Int J Mol Sci. 2024 Nov 4;25(21):11850. doi: 10.3390/ijms252111850

31. McLeod D. Why cotton wool spots should not be regarded as retinal nerve fibre layer infarcts. Br J Ophthalmol. 2005 Feb;89(2):229-37.

32. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7.

33. Sebag J. Vitreous and vision degrading myodesopsia. Prog Retin Eye Res. 2020 Nov;79:100847. doi: 10.1016/j.preteyeres.2020.100847

34. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014 Nov;132(11):1309-16. doi: 10.1001/jamaophthalmol.2014.2350

35. Callan A, Jha S, Valdez L, Tsin A. Cellular and Molecular Mechanisms of Neuronal Degeneration in Early-Stage Diabetic Retinopathy. Curr Vasc Pharmacol. 2024;22(5):325-338. doi: 10.2174/0115701611272737240426050930

36. Wessel MM, Aaker GD, Parlitsis G, et al. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina. 2012 Apr;32(4):785-91. doi: 10.1097/IAE.0b013e3182278b64

37. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53. doi: 10.1056/NEJMoa052187

38. Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015 Jan 31;2015(1):CD006127. doi: 10.1002/14651858.CD006127.pub2

39. Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010 Jun;53(6):1076-83. doi: 10.1007/s00125-010-1697-9

40. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015 Nov 24;314(20):2137-46. doi: 10.1001/jama.2015.15217

41. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006

42. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. If you have diabetes, ensure regular eye screening through your national screening programme or ophthalmologist. Early detection saves sight.